CO2021007370A2 - Anticuerpos que reconocen tau - Google Patents
Anticuerpos que reconocen tauInfo
- Publication number
- CO2021007370A2 CO2021007370A2 CONC2021/0007370A CO2021007370A CO2021007370A2 CO 2021007370 A2 CO2021007370 A2 CO 2021007370A2 CO 2021007370 A CO2021007370 A CO 2021007370A CO 2021007370 A2 CO2021007370 A2 CO 2021007370A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- tau
- recognize tau
- recognize
- specifically bind
- Prior art date
Links
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona anticuerpos que se unen específicamente a tau. Los anticuerpos inhiben o retrasan las patologías asociadas a tau y el deterioro sintomático asociado.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/059895 WO2020096608A1 (en) | 2018-11-08 | 2018-11-08 | Antibodies recognizing tau |
US201862758421P | 2018-11-09 | 2018-11-09 | |
PCT/US2019/060616 WO2020097561A1 (en) | 2018-11-08 | 2019-11-08 | Antibodies recognizing tau |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021007370A2 true CO2021007370A2 (es) | 2021-06-21 |
Family
ID=70610738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0007370A CO2021007370A2 (es) | 2018-11-08 | 2021-06-04 | Anticuerpos que reconocen tau |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220153821A1 (es) |
EP (1) | EP3877410A4 (es) |
JP (1) | JP2022506719A (es) |
KR (1) | KR20210090184A (es) |
CN (1) | CN113454112A (es) |
AU (1) | AU2019377595A1 (es) |
BR (1) | BR112021008624A2 (es) |
CL (1) | CL2021001158A1 (es) |
CO (1) | CO2021007370A2 (es) |
IL (1) | IL283049A (es) |
JO (1) | JOP20210098A1 (es) |
MX (1) | MX2021005411A (es) |
PE (1) | PE20211777A1 (es) |
PH (1) | PH12021551048A1 (es) |
SG (1) | SG11202104549TA (es) |
WO (1) | WO2020097561A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
SG11201809331RA (en) | 2016-05-02 | 2018-11-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
CN116925217B (zh) * | 2023-09-14 | 2024-03-08 | 北京凯祥弘康生物科技有限公司 | 针对Tau蛋白的抗体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031698B1 (ru) * | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
DK2758433T3 (en) * | 2011-09-19 | 2018-01-15 | Axon Neuroscience Se | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE |
PT2935326T (pt) * | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
EP3786182A1 (en) * | 2014-11-19 | 2021-03-03 | Axon Neuroscience SE | Humanized tau antibodies in alzheimer's disease |
CA2986942A1 (en) * | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
PE20190261A1 (es) * | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
EP3487524A4 (en) * | 2016-07-20 | 2020-03-25 | Anahit Ghochikyan | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
PE20212324A1 (es) * | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
-
2019
- 2019-11-08 AU AU2019377595A patent/AU2019377595A1/en active Pending
- 2019-11-08 SG SG11202104549TA patent/SG11202104549TA/en unknown
- 2019-11-08 PE PE2021000683A patent/PE20211777A1/es unknown
- 2019-11-08 JP JP2021524282A patent/JP2022506719A/ja active Pending
- 2019-11-08 BR BR112021008624-2A patent/BR112021008624A2/pt unknown
- 2019-11-08 CN CN201980073684.9A patent/CN113454112A/zh active Pending
- 2019-11-08 JO JOP/2021/0098A patent/JOP20210098A1/ar unknown
- 2019-11-08 KR KR1020217014397A patent/KR20210090184A/ko unknown
- 2019-11-08 EP EP19881978.1A patent/EP3877410A4/en active Pending
- 2019-11-08 MX MX2021005411A patent/MX2021005411A/es unknown
- 2019-11-08 US US17/291,986 patent/US20220153821A1/en active Pending
- 2019-11-08 WO PCT/US2019/060616 patent/WO2020097561A1/en unknown
-
2021
- 2021-05-03 CL CL2021001158A patent/CL2021001158A1/es unknown
- 2021-05-06 PH PH12021551048A patent/PH12021551048A1/en unknown
- 2021-05-09 IL IL283049A patent/IL283049A/en unknown
- 2021-06-04 CO CONC2021/0007370A patent/CO2021007370A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20220153821A1 (en) | 2022-05-19 |
MX2021005411A (es) | 2021-07-06 |
AU2019377595A1 (en) | 2021-05-27 |
CN113454112A (zh) | 2021-09-28 |
CL2021001158A1 (es) | 2021-11-26 |
JOP20210098A1 (ar) | 2023-01-30 |
BR112021008624A2 (pt) | 2021-09-28 |
EP3877410A1 (en) | 2021-09-15 |
EP3877410A4 (en) | 2022-08-10 |
KR20210090184A (ko) | 2021-07-19 |
SG11202104549TA (en) | 2021-05-28 |
PH12021551048A1 (en) | 2021-12-06 |
IL283049A (en) | 2021-06-30 |
WO2020097561A1 (en) | 2020-05-14 |
JP2022506719A (ja) | 2022-01-17 |
PE20211777A1 (es) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019013265A2 (es) | Anticuerpos que reconocen tau | |
CO2018012986A2 (es) | Anticuerpos que reconocen tau | |
CO2021011644A2 (es) | Anticuerpos que reconocen tau | |
CO2021007370A2 (es) | Anticuerpos que reconocen tau | |
CO2018012987A2 (es) | Anticuerpos que reconocen tau | |
CO2021011140A2 (es) | Anticuerpos que reconocen tau | |
CU20210039A7 (es) | Anticuerpos que reconocen tau | |
CU24446B1 (es) | Un anticuerpo monoclonal humanizado que se une a tau | |
MA52152A (fr) | Anticorps | |
DK3743337T3 (da) | Vilkårlig kasselukker | |
DE112019006314A5 (de) | Förderanordnung | |
DE112019001771A5 (de) | Reibteil | |
DK3591122T3 (da) | Hurtigskifter | |
AR128076A1 (es) | Anticuerpos que reconocen la sortilina | |
DK3620213T3 (da) | Retinololiesammensætning | |
DK3814459T3 (da) | Brandstarter | |
DE112019006342A5 (de) | Förderanordnung | |
DK3536861T3 (da) | Hurtigskifter | |
JP1632920S (ja) | 双眼鏡 | |
UA39616S (uk) | Футляр для дрібних речей | |
UA39499S (uk) | Кейс | |
UA39302S (uk) | Кейс | |
UA39593S (uk) | Кейс | |
UA39431S (uk) | Кейс | |
UA39435S (uk) | Кейс |